For Patients

Clinical trials underway

CYT-0851

CYT-0851 is a novel, potent, small molecule inhibitor of monocarboxylate transporter activity proposed for the treatment of cancer patients with relapsed/refractory B-cell malignancies and solid tumors. More information on the trial and enrolling sites can be found at www.clinicaltrials.gov.

LEARN MORE